Two years ago, Coherus BioSciences shelved development of its wholly-owned CHS-2020 biosimilar Eylea (aflibercept) candidate, several times expressing confidence that with its Cimerli (ranibizumab-eqrn) biosimilar, the company had the “ability to not only penetrate a high degree of Lucentis (ranibizumab) [patients], but also those edges of [off-label] Avastin (bevacizumab) and Eylea (aflibercept).”
But in a twist announced on the first day of the annual J.P. Morgan Healthcare conference, the California-based biotech has...






